Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lipson

Showing results (201-210 of 249) with videos related to

Pageof 25
Sort By:
The European Respiratory Journal|October 28, 2024
ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPDR Chad Wade, Fernando J Martinez, Gerard J Criner, et al.
Respiratory Research|November 1, 2019
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trialFrançois Maltais, Leif Bjermer, Edward M Kerwin, et al.
NPJ Primary Care Respiratory Medicine|May 26, 2021
Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPDSandeep Bansal, Martin Anderson, Antonio Anzueto, et al.
Critical Care Medicine|June 24, 2015
A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress SyndromeJason D Christie, Steven Vaslef, Philip K Chang, et al.
Thorax|January 31, 2012
Direct visualisation of collateral ventilation in COPD with hyperpolarised gas MRIHelen Marshall, Martin H Deppe, Juan Parra-Robles, et al.
Respiratory Research|May 31, 2020
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trialsGary T Ferguson, Nicola Brown, Chris Compton, et al.
The American Journal of Gastroenterology|November 1, 1996
GI complications after orthotopic lung transplantationE I Lubetkin, D A Lipson, H I Palevsky, et al.
Journal of the American Heart Association|September 14, 2022
Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT TrialMark T Dransfield, Gerard J Criner, David M G Halpin, et al.
Respirology (Carlton, Vic.)|August 15, 2022
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trialPhilip J Thompson, Gerard J Criner, Mark T Dransfield, et al.
The European Respiratory Journal|April 18, 2020
The effect of exacerbation history on outcomes in the IMPACT trialDavid M G Halpin, Mark T Dransfield, MeiLan K Han, et al.
Pageof 25

Showing results (201-210 of 249) with videos related to

Sort By:
Pageof 25
The European Respiratory Journal|October 28, 2024
ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPDR Chad Wade, Fernando J Martinez, Gerard J Criner, et al.
Respiratory Research|November 1, 2019
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trialFrançois Maltais, Leif Bjermer, Edward M Kerwin, et al.
NPJ Primary Care Respiratory Medicine|May 26, 2021
Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPDSandeep Bansal, Martin Anderson, Antonio Anzueto, et al.
Critical Care Medicine|June 24, 2015
A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress SyndromeJason D Christie, Steven Vaslef, Philip K Chang, et al.
Thorax|January 31, 2012
Direct visualisation of collateral ventilation in COPD with hyperpolarised gas MRIHelen Marshall, Martin H Deppe, Juan Parra-Robles, et al.
Respiratory Research|May 31, 2020
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trialsGary T Ferguson, Nicola Brown, Chris Compton, et al.
The American Journal of Gastroenterology|November 1, 1996
GI complications after orthotopic lung transplantationE I Lubetkin, D A Lipson, H I Palevsky, et al.
Journal of the American Heart Association|September 14, 2022
Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT TrialMark T Dransfield, Gerard J Criner, David M G Halpin, et al.
Respirology (Carlton, Vic.)|August 15, 2022
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trialPhilip J Thompson, Gerard J Criner, Mark T Dransfield, et al.
The European Respiratory Journal|April 18, 2020
The effect of exacerbation history on outcomes in the IMPACT trialDavid M G Halpin, Mark T Dransfield, MeiLan K Han, et al.
Pageof 25